Nov. 14 at 6:37 PM
$XBI $ALT's "modified" data example #2 of 2 from AASLD.
2)
$ALT Presented "less impressive" cT1 data than they initially presented. This critical NIT in the race to get NITs approved in place of biopsy may likely take a hit by this data modification.
Recall,
$ALT hYped cT1 results as a lead indicator for fibrosis improvement (trying to distract from FAILING their Fibrosis Trial Endpoint). These were considerd "Landmark" results by Perspectum (cT1 owner) when they came out, only to modify them for AASLD.
Folks, I can not emphasize this enough...do your Due Diligence. If you're even considering
$ALT, reach out and I'll help you understand the pitfalls they don't want you to see. This was just from AASLD.
Follow/Subscribe for more suggestions and perspective. Would love to hear yours too.
Cheers!
$VKTX $MDGL $NVO
Attachment 1 - Original 24W cT1 data
Attachment 2 - 24W cT1 data presented at AASLD
